Cholesin receptor signalling is active in cardiovascular system-associated adipose tissue and correlates with SGLT2i treatment in patients with diabetes.
Adipose tissue
Cholesin
Diabetes
GPR146
SGLT2i
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
received:
15
04
2024
accepted:
17
06
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
20
6
2024
Statut:
epublish
Résumé
Recently deorphanized G protein-coupled receptor 146 (GPR146) was shown to respond to signal from a newly identified hormone-cholesin-and to play a role in hepatic lipid metabolism. However, the importance of its biological activity in human organism remains elusive, mainly due to the lack of studies on human tissues up to this point. This study aimed to identify the cholesin receptor-associated genes and clinical factors linked with their expression in cardiovascular system and associated adipose tissues. Right cardiac auricle, aortic wall, saphenous vein, and adipose tissue (periaortic-PAT, epicardial-EAT, thymic-TAT) samples were collected during coronary artery bypass grafting. Clinical records of the study participants were assessed for the presence of diabetes, medications taken and serum cholesterol levels. GPR146 mRNA expression in all gathered tissues was assessed with qPCR, and RNA seqencing was performed in selected tissues of 20 individuals to identify pathways associated with GPR146 expression. We included 46 participants [37 male, 23 with type 2 diabetes, median age 68.50 (Q1-Q3: 63.00-72.00) years, BMI 28.39 (26.06-31.49) kg/m GPR146 expression is associated with serum lipids and metabolically-relevant transcriptomic changes in EAT similar to SGLT2i-associated ones.
Sections du résumé
BACKGROUND
BACKGROUND
Recently deorphanized G protein-coupled receptor 146 (GPR146) was shown to respond to signal from a newly identified hormone-cholesin-and to play a role in hepatic lipid metabolism. However, the importance of its biological activity in human organism remains elusive, mainly due to the lack of studies on human tissues up to this point. This study aimed to identify the cholesin receptor-associated genes and clinical factors linked with their expression in cardiovascular system and associated adipose tissues.
METHODS
METHODS
Right cardiac auricle, aortic wall, saphenous vein, and adipose tissue (periaortic-PAT, epicardial-EAT, thymic-TAT) samples were collected during coronary artery bypass grafting. Clinical records of the study participants were assessed for the presence of diabetes, medications taken and serum cholesterol levels. GPR146 mRNA expression in all gathered tissues was assessed with qPCR, and RNA seqencing was performed in selected tissues of 20 individuals to identify pathways associated with GPR146 expression.
RESULTS
RESULTS
We included 46 participants [37 male, 23 with type 2 diabetes, median age 68.50 (Q1-Q3: 63.00-72.00) years, BMI 28.39 (26.06-31.49) kg/m
CONCLUSIONS
CONCLUSIONS
GPR146 expression is associated with serum lipids and metabolically-relevant transcriptomic changes in EAT similar to SGLT2i-associated ones.
Identifiants
pubmed: 38902687
doi: 10.1186/s12933-024-02322-y
pii: 10.1186/s12933-024-02322-y
doi:
Substances chimiques
Receptors, G-Protein-Coupled
0
Sodium-Glucose Transporter 2 Inhibitors
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Subventions
Organisme : National Science Center, Poland
ID : 2022/45/N/NZ4/01206
Organisme : Minister of Education and Science program "Perły Nauki"
ID : PN/01/0025/2022
Informations de copyright
© 2024. The Author(s).
Références
Hu X, Chen F, Jia L, Long A, Peng Y, Li X, et al. A gut-derived hormone regulates cholesterol metabolism. Cell. 2024;187(7):1685-1700.e18.
doi: 10.1016/j.cell.2024.02.024
pubmed: 38503280
Han F, Liu X, Chen C, Liu Y, Du M, Zhou Y, et al. Hypercholesterolemia risk-associated GPR146 is an orphan G-protein coupled receptor that regulates blood cholesterol levels in humans and mice. Cell Res. 2020;30:363–5.
doi: 10.1038/s41422-020-0303-z
pubmed: 32203133
pmcid: 7118070
Yu H, Rimbert A, Palmer AE, Toyohara T, Xia Y, Xia F, et al. GPR146 deficiency protects against hypercholesterolemia and atherosclerosis. Cell. 2019;179(6):1276-1288.e14.
doi: 10.1016/j.cell.2019.10.034
pubmed: 31778654
pmcid: 6889877
Huang J, Xie Y, Chen B, Xia Y, Jiang Y, Sun Z, et al. GPR146 regulates pulmonary vascular remodeling by promoting pulmonary artery smooth muscle cell proliferation through 5-lipoxygenase. Eur J Pharmacol. 2023;961: 176123.
doi: 10.1016/j.ejphar.2023.176123
pubmed: 37926274
Kaczmarek I, Wower I, Ettig K, Kuhn CK, Kraft R, Landgraf K, et al. Identifying G protein-coupled receptors involved in adipose tissue function using the innovative RNA-seq database FATTLAS. iScience. 2023;26(10): 107841.
doi: 10.1016/j.isci.2023.107841
pubmed: 37766984
pmcid: 10520334
Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, et al. SGLT2 inhibitors—the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Therapy. 2024;5(5):1099–124.
doi: 10.1007/s13300-024-01550-5
Marfella R, Scisciola L, D’Onofrio N, Maiello C, Trotta MC, Sardu C, et al. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res. 2022;184: 106448.
doi: 10.1016/j.phrs.2022.106448
pubmed: 36096423
D’Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54:10133.
Clementi E, Corbi G, Boccardi V, Scisciola L. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.
doi: 10.3389/fcvm.2022.1008922
Di Tommaso P, Chatzou M, Floden EW, Barja PP, Palumbo E, Notredame C. Nextflow enables reproducible computational workflows. Nat Biotechnol. 2017;35(4):316–9.
doi: 10.1038/nbt.3820
pubmed: 28398311
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(34):15545–50.
doi: 10.1073/pnas.0506580102
pubmed: 16199517
pmcid: 1239896
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;11:2498–504.
doi: 10.1101/gr.1239303
Lefterova MI, Zhang Y, Steger DJ, Schupp M, Schug J, Cristancho A, et al. PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 2008;22(21):2941–52.
doi: 10.1101/gad.1709008
pubmed: 18981473
pmcid: 2577797
Li Y, Huang X, Yang G, Xu K, Yin Y, Brecchia G, et al. CD36 favours fat sensing and transport to govern lipid metabolism. Prog Lipid Res. 2022;88(88): 101193.
doi: 10.1016/j.plipres.2022.101193
pubmed: 36055468
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science (1979). 2015;347(6220).
Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19:593–606.
doi: 10.1038/s41569-022-00679-9
pubmed: 35296869
pmcid: 8926097
Tinahones F, Salas J, Mayas MD, Ruiz-Villalba A, Macias-Gonzalez M, Garrido-Sanchez L, et al. VEGF gene expression in adult human thymus fat: a correlative study with hypoxic induced factor and cyclooxigenase-2. PLoS ONE. 2009;4(12):e8213.
doi: 10.1371/journal.pone.0008213
pubmed: 20011601
pmcid: 2788242
Szekeres Z, Toth K, Szabados E. The effects of sglt2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):1–9.
doi: 10.3390/metabo11020087
Nagao M, Sasaki J, Tanimura-Inagaki K, Sakuma I, Sugihara H, Oikawa S. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. Cardiovasc Diabetol. 2024. https://doi.org/10.1186/s12933-024-02149-7 .
doi: 10.1186/s12933-024-02149-7
pubmed: 38331780
pmcid: 10854175
Basu D, Huggins LA, Scerbo D, Obunike J, Mullick AE, Rothenberg PL, et al. Mechanism of increased LDL and decreased triglycerides with SGLT2 inhibition HHS public access. Arterioscler Thromb Vasc Biol. 2018;38(9):2207–16.
doi: 10.1161/ATVBAHA.118.311339
pubmed: 30354257
pmcid: 6207215
Ji W, Zhao M, Wang M, Yan W, Liu Y, Ren S, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS ONE. 2017. https://doi.org/10.1371/journal.pone.0179960 .
doi: 10.1371/journal.pone.0179960
pubmed: 29267269
pmcid: 5739347
Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. Circulation. 2022;146:1383–405.
doi: 10.1161/CIRCULATIONAHA.122.061732
pubmed: 36315602
pmcid: 9624240
Hoong CWS, Chua MWJ. SGLT2 inhibitors as calorie restriction mimetics: insights on longevity pathways and age-related diseases. Endocrinology (United States). 2021. https://doi.org/10.1210/endocr/bqab079 .
doi: 10.1210/endocr/bqab079
Masson W, Lavalle-Cobo A, Nogueira JP. Effect of sglt2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells. 2021;10:2150.
doi: 10.3390/cells10082150
pubmed: 34440918
pmcid: 8391573
Cinti F, Leccisotti L, Sorice GP, Capece U, D’Amario D, Lorusso M, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023. https://doi.org/10.1186/s12933-023-02091-0 .
doi: 10.1186/s12933-023-02091-0
pubmed: 38115004
pmcid: 10731727
Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. Guidelines on the management of patients with diabetes: a position of diabetes poland. Curr Top Diabetes. 2022;2(1):1–130.
doi: 10.5114/ctd/146259